维亚生物(01873.HK)续涨近9%拟回购最多1.5亿股
维亚生物(01873.HK)建议於合适时间在公开市场回购最多1.5亿股(相当於股本10%),该股七连升,最高4.22元,创近个半月高,现造4.17元,续升8.9%,一向薄弱成交倍增至469万股,涉资1,933万元。
维亚生物科技主要经营一个领先基於结构新药发现技术平台。股份於今年5月9日以每股4.41元上市,股价於5月15日升至5.45元无以为继,掉头反覆回落,6月25日低见3.15元获承接。
维亚生物公布,拟根据4月中旬股东通过书面决议案所授权回购公司股份,於合适时间在公开市场回购最多1.5亿股(相当於股本10%)。董事会认为现价未能反映其内在价值,为公司回购股份良机,相信透过回购可提升股份价值,从而改善股东回报。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.